Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cationic protein neutralization refers to the process by which cationic (positively charged) proteins or peptides bind to and neutralize negatively charged molecules, most notably bacterial endotoxins such as lipopolysaccharide (LPS). This interaction is a key mechanism in innate immunity, helping to mitigate excessive inflammatory responses during infections, particularly those caused by Gram-negative bacteria. Key molecules involved include Eosinophil Cationic Protein (ECP) and synthetic anti-LPS peptides (SALPs). The mechanism involves electrostatic attraction, structural rearrangement of LPS aggregates, and inhibition of LPS binding to host recognition proteins. It holds therapeutic potential for sepsis and other conditions involving harmful inflammation.
Electrostatic binding of cationic proteins/peptides to negatively charged molecules (e.g., LPS), leading to structural rearrangement and inhibition of host-endotoxin interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cationic Protein Neutralization.